A Phase 1 Study to Evaluate the Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2014
Price : $35 *
At a glance
- Drugs Andecaliximab (Primary) ; Andecaliximab (Primary)
- Indications Chronic obstructive pulmonary disease; Solid tumours; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 23 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Sep 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.